Withdrawal Syndrome After Stopping Opioids Is Not Evidence of Drug Dependence, WHO Committee Says

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 5 No 10
Volume 5
Issue 10

VANCOUVER, BC-Drug dependence is not physical dependence alone, nor is it the same as drug tolerance. "Drug dependence is primarily psychological dependence, or compulsive use of drugs for their mood-altering effects and continued use despite harm," David E. Joranson, MSSW, said at the WHO workshop on cancer pain.

VANCOUVER, BC-Drug dependence is not physical dependence alone,nor is it the same as drug tolerance. "Drug dependence isprimarily psychological dependence, or compulsive use of drugsfor their mood-altering effects and continued use despite harm,"David E. Joranson, MSSW, said at the WHO workshop on cancer pain.

The WHO Expert Committee on Drug Dependence recently clarifiedthat a cancer patient who has been receiving opioids for painand who stops the drug would go through a withdrawal syndromeas evidence of physical dependence, but that individual is notconsidered to be drug dependent.

"Physical dependence by itself is no longer sufficient todefine drug dependence or addiction," Mr. Joranson said."It is important for us to teach this and to clear up themythology about the relationship between opioid analgesia andaddiction."

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Specialties including neurosurgery, radiation oncology, and neuro-rehabilitation all play a notable role in the care of patients with brain tumors.
Treatment-related toxicities during neuro-oncology therapy appear well managed with dose modifications and treatment cycle holds.
The phase 3 NIVOSTOP trial evaluated an anti–PD-1 immunotherapy, nivolumab, in a patient population similar in the KEYNOTE-689 trial.
CAR T-cell therapies appear to be an evolving modality in the treatment of those with intracranial tumors, said Sylvia Kurz, MD, PhD.
Opportunities to further reduce relapses include pembrolizumab-based combination therapy and evaluating the agent’s contribution before and after surgery.
For patients with locally advanced head and neck cancers, the current standard of care for curative therapy has a cure rate of less than 50%.
According to Maurie Markman, MD, patient-reported outcomes pertain to more relevant questions surrounding the impact of therapy for patients.
CancerNetwork® spoke with Neha Mehta-Shah, MD, MSCI, about the clinical landscape for patients undergoing treatment for rare lymphomas.
Related Content